Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma

References

• Parkin, D. M., F. Bray, J. Ferlay, et al. 2005. Global cancer statistics 2002. CA Cancer J. Clin. 55: 74–108 [PubMed: 15761078]
   PubMed Web of Science ®Google Scholar
• Hosgoodiii, H. D., R. S. Chapman, X. He, et al. 2013. History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China. Lung Cancer 81: 343--346 [PubMed: 23891511]
   Google Scholar
• Zhou, Y. C., X. C. Wang, Y. Chen, et al. 2013. Expression of transcription factor SOX4 and its clinical significance in female lung cancer patients in Xuanwei area, Yunnan Province. Zhonghua Zhong Liu Za Zhi 35: 202–206 [PubMed: 23880001]
   PubMedGoogle Scholar
• Lan, Q., R. S. Chapman, D. M. Schreinemachers, et al. 2002. Household stove improvement and risk of lung cancer in Xuanwei, China. J. Natl. Cancer Inst. 94: 826–835 [PubMed: 12048270]
   PubMed Web of Science ®Google Scholar
• Song, S., K. Zhang, H. You, et al. 2010. Significant anti-tumor activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumor. Clin. Exp. Immunol. 162: 75–83 [PubMed: 20735440]
   PubMed Web of Science ®Google Scholar
• Cho, E. I., C. Tan, G. K. Koski, et al. 2010. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck 32: 700–707 [PubMed: 19908319]
   PubMed Web of Science ®Google Scholar
• Xu, F., Y. J. Ye, W. Liu, et al. 2010. Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice. Scand. J. Gastroenterol. 45: 707–713 [PubMed: 20205622]
   PubMed Web of Science ®Google Scholar
• Hu, Z., S. Liu, X. Mai, et al. 2010. Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice. Cell. Immunol. 262: 112–119 [PubMed: 20167310]
   PubMed Web of Science ®Google Scholar
• Rosenblatt, J., B. Vasir, L. Uhl, et al. 2011. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses inpatients with multiple myeloma. Blood 117: 393–402 [PubMed: 21030562]
   PubMed Web of Science ®Google Scholar
• Zhou, J., D. Weng, F. Zhou, et al. 2009. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 58: 1587–1597 [PubMed: 19221746]
   PubMed Web of Science ®Google Scholar
• Haenssle, H. A., S. W. Krause, S. Emmert, et al. 2004. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J. Immunother. 27: 147–155 [PubMed: 14770086]
   PubMed Web of Science ®Google Scholar
• Kjaergaard, J., K. Shimizu, and S. Shu. 2003. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. 225: 65–74 [PubMed: 14698141]
   PubMed Web of Science ®Google Scholar
• Koido, S., Y. Tanaka, D. Chen, et al. 2002. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168: 2111–2117 [PubMed: 11859096]
   PubMed Web of Science ®Google Scholar
• Märten, A., S. Renoth, T. Heinicke, et al. 2003. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14: 483–494 [PubMed: 12691613]
   PubMed Web of Science ®Google Scholar
• Pilla, L., L. Rivoltini, R. Patuzzo, et al. 2009. Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 9:1043–1055 [PubMed: 19591629]
   PubMed Web of Science ®Google Scholar
• Bendandi, M. 2009. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9: 675–681 [PubMed: 19701243]
   PubMed Web of Science ®Google Scholar
• Chen, X., C. H. Chang, and D. M. Goldenberg. 2009. Novel strategies for improved cancer vaccines. Expert Rev. Vaccines 8: 567–576 [PubMed: 19397414]
   PubMed Web of Science ®Google Scholar
• Stephanie, P. H., T. Shiau-Choot, A. A. Kate, et al. 2008. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells againsttumors. Cancer Immunol. Immunother. 57: 63–71 [PubMed: 17609951]
   PubMed Web of Science ®Google Scholar
• Lou, Y., G. Wang, G. Lizée, et al. 2004. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64: 6783–6790 [PubMed: 15374997]
   PubMed Web of Science ®Google Scholar
• Harty, J. T., and V. P. Badovinac. 2008. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 8: 107–119 [PubMed: 18219309]
   PubMed Web of Science ®Google Scholar
• Lutz, M. B., N. Kukutsch, A. L. Ogilvie, et al. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77–92 [PubMed: 10037236]
   PubMed Web of Science ®Google Scholar
• Harris, N., C. Campbell, G. Leros, et al. 1997. Blockade of CD28/B7 co-stimulation by mCTLA4-Hgamma1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur. J. Immunol. 27:155–161 [PubMed: 9022012]
   PubMed Web of Science ®Google Scholar
• Wang, J., S. Saffold, X. Cao, et al. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161: 5516–5524 [PubMed: 9820528]
   PubMed Web of Science ®Google Scholar
• Jaroszeski, M. J., R. Gilbert, and R. Heller. 1994. Detection and quantization of cell--cell electrofusion products by flow cytometry. Anal. Biochem. 216: 271–275 [PubMed: 7513970]
   PubMed Web of Science ®Google Scholar
• Orentas, R. J., D. Schauer, Q. Bin, et al. 2001. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell. Immunol. 213: 4–13 [PubMed: 11747351]
   PubMed Web of Science ®Google Scholar
• Yasuda, T., T. Kamigaki, T. Nakamura, et al. 2006. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol. Rep. 16: 1317–1324 [PubMed: 17089056]
   PubMed Web of Science ®Google Scholar
• Matsumoto, S., H. Saito, S. Tsujitani, et al. 2006. Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8(+) T cells. Cancer Immunol. Immunother. 55: 131–139 [PubMed: 15891883]
   PubMed Web of Science ®Google Scholar
• Ribeiro-Dias, F., M. Russo, F. R. Nascimento, et al. 1998. Thioglycollate-elicited murine macrophages are cytotoxic to Mycoplasma arginini-infected YAC-1 tumor cells. Braz. J. Med. Biol. Res. 31: 1425–1428 [PubMed: 9921279]
   PubMed Web of Science ®Google Scholar
• Yasuda, T., T. Kamigaki, K. Kawasaki, et al. 2007. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56: 1025–1036 [PubMed: 17131118]
   PubMed Web of Science ®Google Scholar
• Marincola, F. M., P. Shamamian, R. B. Alexander, et al. 1994. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153: 1225–1237 [PubMed: 8027550]
   PubMed Web of Science ®Google Scholar
• Restifo, N. P., F. M. Marincola, Y. Kawakami, et al. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88: 100–108 [PubMed: 8537970]
   PubMed Web of Science ®Google Scholar
• Seliger, B., A. Hohne, A. Knuth, et al. 1996. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 56: 1756–1760 [PubMed: 8620489]
   PubMed Web of Science ®Google Scholar
• Iinuma, H., K. Okinaga, R. Fukushima, et al. 2006. Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol. 176: 3461–3469 [PubMed: 16517714]
   PubMed Web of Science ®Google Scholar
• Koido, S., S. Homma, A. Takahara, et al. 2011. Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J. Biomed. Biotechnol. 2011;2011:910836. [PubMed: 21541197]
   Google Scholar
• Suzuki, T., T. Fukuhara, M. Tanaka, et al. 2005. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res. 11: 58–66 [PubMed: 15671528]
   PubMed Web of Science ®Google Scholar
• Yanai, S., Y. Adachi, J. Fuijisawa, et al. 2009. Anti-tumor effects of fusion cells of type 1 dendritic cells and Meth A tumor cells using hemagglutinating virus of Japan-envelope. Int. J. Oncol. 35: 249–255 [PubMed: 19578737]
   PubMed Web of Science ®Google Scholar
• Homma, S., T. Kikuchi, N. Ishiji, et al. 2005. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur. J. Clin. Invest. 35: 279–286 [PubMed: 15816998]
   PubMed Web of Science ®Google Scholar
• Elgert, K. D., D. G. Alleva, and D. W. Mullins. 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64: 275–290 [PubMed: 9738653]
   PubMed Web of Science ®Google Scholar
• Teicher, BA. 2007. Transforming growth factor-beta and the immune response to malignant disease. Clin. Cancer Res. 13: 6247–6251 [PubMed: 17975134]
   PubMed Web of Science ®Google Scholar
• Fricke, I., N. Mirza, J. Dupont, et al. 2007. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13: 4840–4848 [PubMed: 17699863]
   PubMed Web of Science ®Google Scholar
• Houston, A., M. W. Bennett, O'Sullivan G. C., et al. 2003. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br. J. Cancer 89: 1345–1351 [PubMed: 14520470]
   PubMed Web of Science ®Google Scholar
• Takeda, K., Y. Kojima, T. Uno, et al. 2010. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J. Immunol. 184: 5493–5501 [PubMed: 20400706]
   PubMed Web of Science ®Google Scholar
• Szajnik, M., M. Czystowska, M. J. Szczepanski, et al. 2010. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 5: e11469 [PubMed: 20661468]
   Google Scholar
• Shimizu, K., H. Kuriyama, J. Kjaergaard, et al. 2004. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27: 265–272 [PubMed: 15235387]
   PubMed Web of Science ®Google Scholar
• Benencia, F., M. C. Courrèges, and G. Coukos. 2008. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J. Transl. Med. 29: 21 [PubMed: 18445282]
   Google Scholar
• Galea-Lauri, J., D. Darling, G. Mufti, et al. 2002. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51: 299–310 [PubMed: 12111118]
   PubMed Web of Science ®Google Scholar
• Soruri, A., A. Fayyazi, C. Neumann, et al. 2001. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dentritic cell/melanoma cell hybridomas. Cancer Immunol. Immunother. 50: 307–314 [PubMed: 11570584]
   PubMed Web of Science ®Google Scholar
• Eggert, A. A., M. W. Schreurs, O. C. Boerman, et al. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59:3340–3345 [PubMed: 10416590]
   PubMed Web of Science ®Google Scholar
• Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86–89 [PubMed: 9510252]
   PubMed Web of Science ®Google Scholar